A neutralizing monoclonal antibody for hospitalized patients with Covid-19
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A neutralizing monoclonal antibody for hospitalized patients with Covid-19. / ACTIV-3/TICO LY-CoV555 Study Group.
In: New England Journal of Medicine, Vol. 384, No. 10, 11.03.2021, p. 905-914.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A neutralizing monoclonal antibody for hospitalized patients with Covid-19
AU - Lundgren, J. D.
AU - Grund, B.
AU - Barkauskas, C. E.
AU - Holland, T. L.
AU - Gottlieb, R. L.
AU - Sandkovsky, U.
AU - Brown, S. M.
AU - Knowlton, K. U.
AU - Self, W. H.
AU - Files, D. C.
AU - Jain, M. K.
AU - Benfield, T.
AU - Bowdish, M. E.
AU - Leshnower, B. G.
AU - Baker, J. V.
AU - Jensen, J. U.
AU - Gardner, E. M.
AU - Ginde, A. A.
AU - Harris, E. S.
AU - Johansen, I. S.
AU - Markowitz, N.
AU - Matthay, M. A.
AU - Østergaard, L.
AU - Chang, C. C.
AU - Davey, V. J.
AU - Goodman, A.
AU - Higgs, E. S.
AU - Murray, D. D.
AU - Murray, T. A.
AU - Paredes, R.
AU - Parmar, M. K.B.
AU - Phillips, A. N.
AU - Reilly, C.
AU - Sharma, S.
AU - Dewar, R. L.
AU - Teitelbaum, M.
AU - Wentworth, D.
AU - Cao, H.
AU - Klekotka, P.
AU - Babiker, A. G.
AU - Gelijns, A. C.
AU - Kan, V. L.
AU - Polizzotto, M. N.
AU - Thompson, B. T.
AU - Lane, H. C.
AU - Neaton, J. D.
AU - ACTIV-3/TICO LY-CoV555 Study Group
N1 - Publisher Copyright: Copyright © 2020 Massachusetts Medical Society.
PY - 2021/3/11
Y1 - 2021/3/11
N2 - Background: LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19. Methods: In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or matching placebo. In addition, all the patients received high-quality supportive care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemental oxygen and glucocorticoids. LY-CoV555 (at a dose of 7000 mg) or placebo was administered as a single intravenous infusion over a 1-hour period. The primary outcome was a sustained recovery during a 90-day period, as assessed in a time-to-event analysis. An interim futility assessment was performed on the basis of a seven-category ordinal scale for pulmonary function on day 5. Results: On October 26, 2020, the data and safety monitoring board recommended stopping enrollment for futility after 314 patients (163 in the LY-CoV555 group and 151 in the placebo group) had undergone randomization and infusion. The median interval since the onset of symptoms was 7 days (interquartile range, 5 to 9). At day 5, a total of 81 patients (50%) in the LY-CoV555 group and 81 (54%) in the placebo group were in one of the two most favorable categories of the pulmonary outcome. Across the seven categories, the odds ratio of being in a more favorable category in the LY-CoV555 group than in the placebo group was 0.85 (95% confidence interval [CI], 0.56 to 1.29; P = 0.45). The percentage of patients with the primary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.56; 95% CI, 0.78 to 3.10; P = 0.20). The rate ratio for a sustained recovery was 1.06 (95% CI, 0.77 to 1.47). Conclusions: Monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ failure.
AB - Background: LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19. Methods: In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or matching placebo. In addition, all the patients received high-quality supportive care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemental oxygen and glucocorticoids. LY-CoV555 (at a dose of 7000 mg) or placebo was administered as a single intravenous infusion over a 1-hour period. The primary outcome was a sustained recovery during a 90-day period, as assessed in a time-to-event analysis. An interim futility assessment was performed on the basis of a seven-category ordinal scale for pulmonary function on day 5. Results: On October 26, 2020, the data and safety monitoring board recommended stopping enrollment for futility after 314 patients (163 in the LY-CoV555 group and 151 in the placebo group) had undergone randomization and infusion. The median interval since the onset of symptoms was 7 days (interquartile range, 5 to 9). At day 5, a total of 81 patients (50%) in the LY-CoV555 group and 81 (54%) in the placebo group were in one of the two most favorable categories of the pulmonary outcome. Across the seven categories, the odds ratio of being in a more favorable category in the LY-CoV555 group than in the placebo group was 0.85 (95% confidence interval [CI], 0.56 to 1.29; P = 0.45). The percentage of patients with the primary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.56; 95% CI, 0.78 to 3.10; P = 0.20). The rate ratio for a sustained recovery was 1.06 (95% CI, 0.77 to 1.47). Conclusions: Monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ failure.
U2 - 10.1056/NEJMoa2033130
DO - 10.1056/NEJMoa2033130
M3 - Journal article
C2 - 33356051
AN - SCOPUS:85099949020
VL - 384
SP - 905
EP - 914
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 10
ER -
ID: 286418621